TY - JOUR
T1 - Prevalence and Management of Adult Obesity in a Large U.S. Academic Health System
AU - Lumsden, Rebecca H.
AU - Pagidipati, Neha J.
AU - Phelan, Matthew P.
AU - Chiswell, Karen
AU - Peterson, Eric D.
N1 - Funding Information:
Dr. Pagidipati has received research grants from Amgen, Regeneron Pharmaceuticals, Sanofi-Aventis, and Verily Life Sciences. Dr. Peterson has received research support and consulting from Amgen, AstraZenica, Bayer AG, NovoNordisc, Sanofi, Regenron, and Janssen. No other financial disclosures were reported by the authors of this paper. No funds were used to directly support this project.
Funding Information:
Dr. Pagidipati has received research grants from Amgen, Regeneron Pharmaceuticals, Sanofi-Aventis, and Verily Life Sciences. Dr. Peterson has received research support and consulting from Amgen, AstraZenica, Bayer AG, NovoNordisc, Sanofi, Regenron, and Janssen. No other financial disclosures were reported by the authors of this paper. No funds were used to directly support this project.
Publisher Copyright:
© 2020 American Journal of Preventive Medicine
PY - 2020/6
Y1 - 2020/6
N2 - Introduction: Both medication and surgical interventions can be used to treat obesity, yet their use and effectiveness in routine clinical practice are not clear. This study sought to characterize the prevalence and management of patients with obesity within a large U.S. academic medical center. Methods: All patients aged ≥18 years who were seen in a primary care clinic within the Duke Health System between 2013 and 2016 were included. Patients were categorized according to baseline BMI as underweight or normal weight (<25 kg/m2), overweight (25–29.9 kg/m2), Class I obesity (30–34.9 kg/m2), Class II obesity (35–39.9 kg/m2), and Class III obesity (≥40 kg/m2). Baseline characteristics and use of weight loss medication were assessed by BMI category. Predicted change in BMI was modeled over 3 years. All data were analyzed between 2017 and 2018. Results: Of the 173,462 included patients, most were overweight (32%) or obese (40%). Overall, <1% (n=295) of obese patients were prescribed medication for weight loss or underwent bariatric surgery within the 3-year study period. Most patients had no change in BMI class (70%) at 3 years. Conclusions: Despite a high prevalence of obesity within primary care clinics of a large, U.S. academic health center, the use of pharmacologic and surgical therapies was low, and most patients had no weight change over 3 years. This highlights the significant need for improvement in obesity care at a health system level.
AB - Introduction: Both medication and surgical interventions can be used to treat obesity, yet their use and effectiveness in routine clinical practice are not clear. This study sought to characterize the prevalence and management of patients with obesity within a large U.S. academic medical center. Methods: All patients aged ≥18 years who were seen in a primary care clinic within the Duke Health System between 2013 and 2016 were included. Patients were categorized according to baseline BMI as underweight or normal weight (<25 kg/m2), overweight (25–29.9 kg/m2), Class I obesity (30–34.9 kg/m2), Class II obesity (35–39.9 kg/m2), and Class III obesity (≥40 kg/m2). Baseline characteristics and use of weight loss medication were assessed by BMI category. Predicted change in BMI was modeled over 3 years. All data were analyzed between 2017 and 2018. Results: Of the 173,462 included patients, most were overweight (32%) or obese (40%). Overall, <1% (n=295) of obese patients were prescribed medication for weight loss or underwent bariatric surgery within the 3-year study period. Most patients had no change in BMI class (70%) at 3 years. Conclusions: Despite a high prevalence of obesity within primary care clinics of a large, U.S. academic health center, the use of pharmacologic and surgical therapies was low, and most patients had no weight change over 3 years. This highlights the significant need for improvement in obesity care at a health system level.
UR - http://www.scopus.com/inward/record.url?scp=85084581343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084581343&partnerID=8YFLogxK
U2 - 10.1016/j.amepre.2020.01.018
DO - 10.1016/j.amepre.2020.01.018
M3 - Article
C2 - 32444000
AN - SCOPUS:85084581343
SN - 0749-3797
VL - 58
SP - 817
EP - 824
JO - American Journal of Preventive Medicine
JF - American Journal of Preventive Medicine
IS - 6
ER -